Samuel S Engel

Title: Samuel S Engel: Innovator in Cardiovascular Treatment

Introduction

Samuel S Engel is a notable inventor based in New York, NY (US). He has made significant contributions to the field of medicine, particularly in the treatment of cardiovascular diseases. His innovative work has led to the development of methods that utilize SGLT-2 inhibitors for reducing the risk of cardiovascular events.

Latest Patents

Samuel S Engel holds a patent for "Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors." This invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof. The patent focuses on treating, reducing the risk of, and preventing heart failure, myocardial infarction, cardiovascular disease, or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, as well as in animals with pre-diabetes or those with type 2 or type 1 diabetes mellitus.

Career Highlights

Throughout his career, Samuel S Engel has worked with prominent companies in the pharmaceutical industry. He has been associated with Merck Sharp & Dohme Corporation and Pfizer Corporation, where he has contributed to various research and development projects aimed at improving health outcomes.

Collaborations

Samuel has collaborated with notable colleagues, including Brett Lauring and Steven G Terra. These partnerships have played a crucial role in advancing his research and innovations in the field of cardiovascular treatment.

Conclusion

Samuel S Engel's contributions to the medical field, particularly through his patent on SGLT-2 inhibitors, highlight his commitment to improving cardiovascular health. His work continues to influence the development of effective treatments for cardiovascular diseases.